Unlocking the Potential of ARPC3P5 as a Drug Target and Biomarker

Target Name: ARPC3P5

NCBI ID: G441131

ARPC3P5

Other Name(s): Actin related protein 2/3 complex subunit 3 pseudogene 5 | actin related protein 2/3 complex subunit 3 pseudogene 5

Unlocking the Potential of ARPC3P5 as a Drug Target and Biomarker

Apoptosis, the process of natural cell death, is a crucial event in the regulation of cell growth and development. The actin-related protein 2/3 complex subunit 3 (ARPC3P5) plays a critical role in cell apoptosis, which is essential for maintaining tissue homeostasis and regeneration. aberrant cell apoptosis can lead to various diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases. Therefore, identifying and targeting ARPC3P5 as a drug target or biomarker holds great promise for the development of new therapeutic approaches.

ARPC3P5: Structure and Function

The ARPC3P5 protein is a 160-kDa protein that belongs to the actin-related protein 2/3 complex subunit 3 family. This protein is expressed in various tissues, including muscle, heart, liver, and brain, and plays a key role in cell apoptosis. ARPC3P5 is composed of three distinct subunits: ARPC3P5A, ARPC3P5B, and ARPC3P5C. The ARPC3P5A subunit is the catalytic subunit, responsible for the formation of the active complex with AP-1. The ARPC3P5B subunit is the regulatory subunit, which interacts with the AP-1 protein to regulate the activity of ARPC3P5A. The ARPC3P5C subunit is a cytoplasmic protein that interacts with ARPC3P5A and may play a role in regulating the localization of ARPC3P5A to the plasma membrane.

ARPC3P5 is involved in the regulation of cell apoptosis, which is a critical process for maintaining tissue homeostasis and regeneration. Activated ARPC3P5 can induce cell apoptosis, while inhibited ARPC3P5 can protect cells from apoptosis. Therefore, targeting ARPC3P5 as a drug target or biomarker may be an effective way to treat various diseases associated with aberrant cell apoptosis.

Drug Targeting and Biomarker Assays

Drug targeting ARPC3P5 as a potential drug target involves the development of small molecules or other compounds that can inhibit the activity of ARPC3P5A or interact with its regulatory subunit, ARPC3P5B. To identify potential drug targets, a variety of screening approaches can be used, including high-throughput screening (HTS), virtual screening, and bioinformatics analysis.

One of the most promising strategies for targeting ARPC3P5 is the development of small molecules that can inhibit the activity of ARPC3P5A. These small molecules can be derived from natural products, such as herbal compounds, or from synthetic compounds. To optimize the drug candidates, a variety of screening approaches can be used, including cell-based assays, in vitro assays, and in vivo assays. For example, a high-throughput screening library can be screened against various cell types to identify compounds that inhibit the activity of ARPC3P5A. Additionally, virtual screening can be used to predict the potential binding sites of small molecules and identify compounds with unique structural features.

Another approach for targeting ARPC3P5 is the development of biomarkers that can be used to monitor the activity of ARPC3P5A. These biomarkers can be derived from ARPC3P5A or ARPC3P5B, and can be used to monitor the activity of ARPC3P5A in cell-based assays or in vitro assays. For example, a GFP-fused construct that expresses ARPC3P5A can be used to monitor the activity of

Protein Name: Actin Related Protein 2/3 Complex Subunit 3 Pseudogene 5

The "ARPC3P5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ARPC3P5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets